4.7 Article

RiboCas: A Universal CRISPR-Based Editing Tool for Clostridium

Journal

ACS SYNTHETIC BIOLOGY
Volume 8, Issue 6, Pages 1379-1390

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/acssynbio.9b00075

Keywords

Clostridium; riboswitch; inducible expression; CRISPR; synthetic biology

Funding

  1. Biotechnology and Biological Sciences Research Council [BB/J014508/1, BB/L013940/1, 642068]
  2. BBSRC [BB/L013940/1] Funding Source: UKRI
  3. MRC [G0601176] Funding Source: UKRI
  4. Biotechnology and Biological Sciences Research Council [BB/L013940/1] Funding Source: researchfish

Ask authors/readers for more resources

Members of the genus Clostridium represent a diverse assemblage of species exhibiting both medical and industrial importance. Deriving both a greater understanding of their biology, while at the same time enhancing their exploitable properties, requires effective genome editing tools. Here, we demonstrate the first implementation in the genus of theophylline-dependent, synthetic riboswitches exhibiting a full set of dynamic ranges, also suitable for applications where tight control of gene expression is required. Their utility was highlighted by generating a novel riboswitch-based editing tool-RiboCas-that overcomes the main obstacles associated with CRISPR/Cas9 systems, including low transformation efficiencies and excessive Cas9 toxicity. The universal nature of the tool was established by obtaining chromosomal modifications in C. pasteurianum, C. difficile, and C. sporogenes, as well as by carrying out the first reported example of CRISPR-targeted gene disruption in C. botulinum. The high efficiency (100% mutant generation) and ease of application of RiboCas make it suitable for use in a diverse range of microorganisms.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available